Table 2.

Summary of the characteristics of BoNT/A interventions in the included literature.

Individual	Average Masseter Mass (g)	Generic Name/Brand	Dose/Volume (U/ml)	Average BoNT/A Dose Per Masseter Mass (U/g)
Mouse [51,62,63,66]	0.075 [51]	Onabotulinumtoxin A; Botox®, Allergan Chile, Santiago, Chile [51,62] Onabotulinumtoxin A; Botox®, Allergan, Plc, Parsippany-Troy Hills, NJ, USA [63,66]	0.2–0.3/0.01–0.03	3.3
Rat [64,65,68,72]	1.1 [64]	Onabotulinumtoxin A; Botox®, Allergan Inc., Irvine, CA, USA [64,65,68] Onabotulinumtoxin A; Botox®, Allergan Pharmaceuticals, Dublin, Ireland [72]	1–7.5/0.1–0.3	4.3
Rabbit [67,70]	7.9 [70]	Onabotulinumtoxin A; Botox®, Allergan Inc., Irvine, CA, USA [67,70]	10/0.25	1.2
Human [8,71]	20.14 [83]	Onabotulinumtoxin A; Neuronox®, Medytox Inc., Seoul, Korea [8] Abobotulinum A; Dysport®, Ipsen Biopharm Ltd, Wrexham, UK [71]	25/0.5 [8] 120/0.6 [71]	3.6